Next Article in Journal
The Chemical Components of Sesbania grandiflora Root and Their Antituberculosis Activity
Next Article in Special Issue
Differential Cellular and Molecular Effects of Butyrate and Trichostatin A on Vascular Smooth Muscle Cells
Previous Article in Journal
Phytomedicine in Otorhinolaryngology and Pulmonology: Clinical Trials with Herbal Remedies
Previous Article in Special Issue
Epigenetic Mechanisms and Therapeutic Perspectives for Neurodevelopmental Disorders
Open AccessReview

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)

Département de Pharmacologie, Service d’ Hématologie et Oncologie, Centre de Recherche, CHU-Saint-Justine, Université de Montréal, Montréal, Québec H3T 1C5, Canada
Pharmaceuticals 2012, 5(8), 875-881;
Received: 31 May 2012 / Revised: 16 August 2012 / Accepted: 17 August 2012 / Published: 21 August 2012
(This article belongs to the Special Issue Epigenetic Therapies and Biomarkers)
5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine, Dacogen®) and 5-azacytidine (5-AC, Vidaza®) are epigenetic agents that have been approved for the clinical treatment of the hematological malignancy myelodysplastic syndrome (MDS) and are currently under clinical evaluation for the treatment of acute myeloid leukemia (AML). Most investigators currently classify 5-AZA-CdR and 5-AC as inhibitors of DNA methylation, which can reactivate tumor suppressor genes silenced by this epigenetic event. Examination of the pharmacology of these analogues reveals important differences with respect to their molecular mechanism of action. The action of 5-AZA-CdR is due to its incorporation into DNA. 5-AC is a riboside analogue that is incorporated primarily into RNA. A small fraction of 5-AC is converted to its deoxyribose form by ribonucleotide reductase and subsequently incorporated into DNA. The incorporation of 5-AC into RNA can interfere with the biological function of RNA and result in an inhibition protein synthesis. Microarray analysis revealed that both these analogues target the expression of different cohorts of genes. Preclinical studies show that 5-AZA-CdR is a more effective antileukemic agent than 5-AC. One explanation for this observation is that 5-AC blocks the progression of some leukemic cells from G1 into S phase, and this protects these cells from the chemotherapeutic action of this riboside analogue related to its incorporation into DNA. However, differences in chemotherapeutic efficacy of these related analogues have not been clearly demonstrated in clinical trials in patients with hematological malignancies. These observations should be taken into consideration in the design of new clinical trials using 5-AZA-CdR or 5-AC in patients with MDS and AML. View Full-Text
Keywords: 5-aza-2′-deoxycytidine; 5-azacytidine; leukemia; chemotherapy; DNA methylation 5-aza-2′-deoxycytidine; 5-azacytidine; leukemia; chemotherapy; DNA methylation
Show Figures

Figure 1

MDPI and ACS Style

Momparler, R.L. A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza). Pharmaceuticals 2012, 5, 875-881.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop